PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35487151-0	2022	Inhibitory mechanism of Ambroxol and Bromhexine Hydrochlorides as potent blockers of molecular interaction between SARS-CoV-2 spike protein and human angiotensin-converting Enzyme-2.	Bromhexine	37-62	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	126-131	
33608407-15	2021	We therefore caution against use of Bromhexine in higher dosage until its effects on SARS-CoV-2 spike activation are better understood.	Bromhexine	36-46	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	96-101	
32995775-4	2020	Herein, we discovered that Ambroxol hydrochloride (AMB), and its progenitor, Bromhexine hydrochloride (BHH), both clinically approved drugs are potent effective modulators of the key interaction between the receptor binding domain (RBD) of SARS-CoV-2 spike protein and human ACE2.	Bromhexine	77-101	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	251-256	
32995775-4	2020	Herein, we discovered that Ambroxol hydrochloride (AMB), and its progenitor, Bromhexine hydrochloride (BHH), both clinically approved drugs are potent effective modulators of the key interaction between the receptor binding domain (RBD) of SARS-CoV-2 spike protein and human ACE2.	Bromhexine	103-106	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	251-256